Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has expanded a contract manufacturing agreement originally signed in August 2018, increasing the value from KRW 144.6B to KRW 215.9B upon the client’s request and extending the contract term through 2037.
📊 [Key Disclosure Details & Financial Summary]
- Original Disclosure Date: 2018-08-14
- Amendment Date: 2026-06-22
- Reason for Amendment: Contract value adjustment requested by the client
- Comparison of Key Contract Terms:
- Contract Value:
- Before Amendment: KRW 144,610,010,460 (USD 127,555,800)
- After Amendment: KRW 215,942,414,460 (USD 190,475,800, Increased by USD 62,920,000)
- Ratio to Revenue:
- Before Amendment: 31.12% (Based on FY2017 consolidated revenue of KRW 464,629,334,143)
- After Amendment: 46.48% (Based on FY2017 consolidated revenue of KRW 464,629,334,143)
- Contract Period:
- Before Amendment: 2018-08-14 ~ 2028-12-31
- After Amendment: 2018-08-14 ~ 2037-12-31
- Non-disclosure Period:
- Before Amendment: 2028-12-31
- After Amendment: 2037-12-31 (Due to business confidentiality)
- Contract Value:
- Other Key Contract Details:
- Contract Name: Contract Manufacturing Agreement for Pharmaceuticals
- Counterparty: Asian-based Pharmaceutical Company (Undisclosed until December 31, 2037, due to trade secret protection)
- Applied Exchange Rate: Applied initial FX rate of USD/KRW 1,133.70 as of August 14, 2018
- Other Notes: Contract term and amount are subject to change upon mutual agreement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Future Amended Disclosures Regarding Changes in Contract Value or Period
This filing is a correction disclosure regarding changes to the contract value and period of a previously executed manufacturing agreement. Verifying whether further adjustments to the contract value or period occur through mutual agreement is important for identifying any subsequent changes to the finalized contract terms. Relevant updates can be verified in future amended disclosures and upcoming periodic reports.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
